Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 22,018 matching trials from the local directory fallback.

Filters: Recruiting Clear all

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Myeloid Leukemia With Variant MLL Translocations, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Chemotherapy-Related Leukemia, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Gene Mutation, Myelodysplastic/Myeloproliferative Neoplasm, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Adult Acute Lymphoblastic Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan, Rituximab, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Biological · Drug · Other + 2 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Monoclonal B-Cell Lymphocytosis, Multiple Myeloma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2029
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Allergic Reactions, Allergy, Anaphylaxis, Biomarkers / Blood
Interventions: Thromboelastogram; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 12 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Anxiety, Depression, Problematic Phone Use Behavior
Interventions: Mindwire; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 13 Years to 19 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: 14C-VX-407; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS, Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions: Placebo, SUN-627; Other · Drug
Lead sponsor: Sundance Biosciences, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Stony Brook, New York + 4 more

Conditions: Healthy Participants
Interventions: KT-621; Drug
Lead sponsor: Kymera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), GastroEsophageal Cancer, Pancreatic Cancer, Urothelial Cancer
Interventions: MGC030; Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Lake Success, New York

Conditions: Cancer
Interventions: Medisafe Medication Management Program, Pharmacist-Led Medication Review; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Parkinson's Disease (PD)
Interventions: adaptive DBS (aDBS); Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 45 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Cancer
Interventions: Social connectedness intervention; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 22 Years to 39 Years
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Major Depression
Interventions: NRX-101, TMS; Drug · Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Obesity or Overweight
Interventions: Lenbelintide, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 41
States / cities: Dothan, Alabama • Huntsville, Alabama • Mesa, Arizona + 38 more

Conditions: Insulin Stimulated
Interventions: Insulin 80mU/m2*min; Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Glioblastoma
Interventions: Biospecimen Collection, Electronic Health Record Review, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Asthma
Interventions: Placebo, tilrekimig; Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 13
States / cities: Bakersfield, California • Miami, Florida • White Marsh, Maryland + 10 more

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Biopsy, Durvalumab, Histotripsy; Procedure · Drug · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Avulsion Fracture
Interventions: Prolonged Immobilization (Casting), Standard of Care (SOC); Procedure
Lead sponsor: Texas Scottish Rite Hospital for Children; Other
Eligibility: 5 Years to 12 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Schizophrenia Spectrum Disorders (SSD)
Interventions: Psychosocial intervention group; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 9 Years to 26 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes Mellitus, Type 1 Diabetes
Interventions: Culturally and linguistically tailored onboarding and support program, Medtronic MiniMed 780G Insulin Pump System; Other · Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 10 Years to 20 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Prosthetic Joint Infection of Knee
Interventions: Debridement, Antibiotics, Implant Retention, Intervention 1: Alternating Magnetic Field Treatment, Intervention 2 - Sham Treatment; Procedure · Device
Lead sponsor: Solenic Medical, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: New Albany, Ohio • Tulsa, Oklahoma

Conditions: Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,085 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Follicular Helper T-Cell Lymphoma, Follicular-Type, Recurrent Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Recurrent Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Follicular Helper T-Cell Lymphoma, Follicular-Type, Refractory Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Refractory Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Azacitidine, Belinostat, Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Pralatrexate, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 2
States / cities: Duarte, California • Newnan, Georgia

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 423 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Personalized NK Cell Therapy in CBT

Family Study of Lymphoproliferative Disorders

Maximum Lysis on Thromboelastography as a Marker of Systemic Severity in Acute Allergic Reactions

The Mindful Smartphone Use Study

Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

A Study to Evaluate Different Oral Formulations of KT-621

A Study of MGC030 in Participants With Advanced Solid Tumors

Improving Adherence to Chronic Disease Medication Regimens Among Patients With Recently Diagnosed Cancer

Investigating Basal Ganglia-Cortical Physiology During Sleep and Its Modulation by Adaptive Deep Brain Stimulation in Parkinson Disease

Keep Social Randomized Controlled Trial for Young Adults With Cancer

Single Day of Ultra-accelerated TMS With a Single Dose of NRX-101

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Genetics of Skeletal Muscle Insulin Resistance

Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients

A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma

Lateral Ankle Treatment

Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention

Supporting Medtronic 780G Insulin Pump Adoption in Latino Patients: A Spanish - Language Training Initiative

Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma

Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care